Create a free QxMD account to take advantage of the features offered by Read like saving your papers and creating collections.

Get Started

JOURNAL ARTICLE

Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance

James A McCubrey, Linda S Steelman, Richard A Franklin, Steven L Abrams, William H Chappell, Ellis W T Wong, Brian D Lehmann, David M Terrian, Jorg Basecke, Franca Stivala, Massimo Libra, Camilla Evangelisti, Alberto M Martelli

Advances in Enzyme Regulation 2007, 47: 64-103

No abstract text is available yet for this article.

Full Text Links

Find Full Text Links for this Article

Discussion

You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. L S Steelman, R A Franklin, S L Abrams, W Chappell, C R Kempf, J Bäsecke, F Stivala, M Donia, P Fagone, F Nicoletti, M Libra, P Ruvolo, V Ruvolo, C Evangelisti, A M Martelli, J A McCubrey Leukemia 2011, 25 (7): 1080-94

Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance. J A McCubrey, S L Abrams, G Ligresti, N Misaghian, E W T Wong, L S Steelman, J Bäsecke, J Troppmair, M Libra, F Nicoletti, S Molton, M McMahon, C Evangelisti, A M Martelli Leukemia 2008, 22 (11): 2080-90

Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors. Florian Ewald, Dominik Nörz, Astrid Grottke, Bianca T Hofmann, Björn Nashan, Manfred Jücker Investigational New Drugs 2014, 32 (6): 1144-54

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. William H Chappell, Linda S Steelman, Jacquelyn M Long, Ruth C Kempf, Stephen L Abrams, Richard A Franklin, Jörg Bäsecke, Franca Stivala, Marco Donia, Paolo Fagone, Graziella Malaponte, Maria C Mazzarino, Ferdinando Nicoletti, Massimo Libra, Danijela Maksimovic-Ivanic, Sanja Mijatovic, Giuseppe Montalto, Melchiorre Cervello, Piotr Laidler, Michele Milella, Agostino Tafuri, Antonio Bonati, Camilla Evangelisti, Lucio Cocco, Alberto M Martelli, James A McCubrey Oncotarget 2011, 2 (3): 135-64

The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. Stephen L Abrams, Linda S Steelman, John G Shelton, Ellis W T Wong, William H Chappell, Jörg Bäsecke, Franca Stivala, Marco Donia, Ferdinando Nicoletti, Massimo Libra, Alberto M Martelli, James A McCubrey Cell Cycle 2010, 9 (9): 1781-91

Dequalinium induces cytotoxicity in human leukemia NB4 cells by downregulation of Raf/MEK/ERK and PI3K/Akt signaling pathways and potentiation of specific inhibitors of these pathways. Ana I García-Pérez, Eva Galeano, Elena Nieto, M Cristina Estañ, Pilar Sancho Leukemia Research 2014, 38 (7): 795-803

Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. James A McCubrey, Linda S Steelman, C Ruth Kempf, William H Chappell, Stephen L Abrams, Franca Stivala, Graziella Malaponte, Ferdinando Nicoletti, Massimo Libra, Jörg Bäsecke, Danijela Maksimovic-Ivanic, Sanja Mijatovic, Giuseppe Montalto, Melchiorre Cervello, Lucio Cocco, Alberto M Martelli Journal of Cellular Physiology 2011, 226 (11): 2762-81

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. James A McCubrey, Linda S Steelman, William H Chappell, Stephen L Abrams, Richard A Franklin, Giuseppe Montalto, Melchiorre Cervello, Massimo Libra, Saverio Candido, Grazia Malaponte, Maria C Mazzarino, Paolo Fagone, Ferdinando Nicoletti, Jörg Bäsecke, Sanja Mijatovic, Danijela Maksimovic-Ivanic, Michele Milella, Agostino Tafuri, Francesca Chiarini, Camilla Evangelisti, Lucio Cocco, Alberto M Martelli Oncotarget 2012, 3 (10): 1068-111

Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells. Michele T Yip-Schneider, Patrick J Klein, Sabrina C Wentz, Amer Zeni, Alex Menze, C Max Schmidt Journal of Pharmacology and Experimental Therapeutics 2009, 329 (3): 1063-70

PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. Roberto Gedaly, Paul Angulo, Jonathan Hundley, Michael F Daily, Changguo Chen, Alvaro Koch, B Mark Evers Anticancer Research 2010, 30 (12): 4951-8

Make the most of Read.
Download the mobile app.

Want full text access to this paper?

Use Read by QxMD to access full text via your institution or open access sources.

Read also provides personalized recommendations to keep you up to date in your field.

Existing User

New to Read

Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance

Discussion

Related Papers

Want full text access to this paper?

Save your favorite articles in one place with a free QxMD account.

Read

Search Tips